Novartis

Fabrikstrasse 2, 4056 Basel
Novartis   link
Discipline: Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Pharmacology - Health - Mar 28
Patients & Caregivers Healthcare Professionals Society & ESG Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months 1 -   Prespecified exploratory analysis based on safety reporting from the three trials, showed fewe
Pharmacology - Health - Mar 27

Patients & Caregivers Healthcare Professionals Society & ESG - EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data 1 -   If approved, Cosentyx would become the first fully-human IL

Pharmacology - Business - Mar 26

Patients & Caregivers Healthcare Professionals Society & ESG - Collaboration to address product development and scale up challenges posed by current pandemic   Basel, March 26, 2020 - Today, Novartis and a consortium of life sciences companies announced an important collaboration to acceler

Pharmacology - Health - Mar 24

Patients & Caregivers Healthcare Professionals Society & ESG Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones -   In addition to meeting both co-primary efficacy endp

Pharmacology - Health - Mar 19

Patients & Caregivers Healthcare Professionals Society & ESG - Zolgensma (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at diagnosis -   Zolgensma has demonstrat

Pharmacology - Health - Mar 17

Patients & Caregivers Healthcare Professionals Society & ESG - Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak -   Novartis to join collaborative R&D efforts with the Bill &

Pharmacology - Business - Mar 2

Patients & Caregivers Healthcare Professionals Society & ESG - Princeton, New Jersey, March 2, 2020 - Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department's more than three-year-long antitrust investigation into the U.S. generic drug industry.

Pharmacology - Health - Mar 27

Patients & Caregivers Healthcare Professionals Society & ESG - Zolgensma (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and a clinical diagnosis of Type

Pharmacology - Health - Mar 24

Patients & Caregivers Healthcare Professionals Society & ESG - SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12, twice the clinically mea

Pharmacology - Health - Mar 20

Patients & Caregivers Healthcare Professionals Society & ESG - Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.

Pharmacology - Health - Mar 18

Patients & Caregivers Healthcare Professionals Society & ESG Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous

Pharmacology - Health - Mar 3

Patients & Caregivers Healthcare Professionals Society & ESG - EDCTP grants the PAMAfrica research consortium ¤21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional ¤22 million.

Business - Feb 28

Patients & Caregivers Healthcare Professionals Society & ESG - Shareholders approve 23 rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5% 1 yield and approximately 54% payout of free cash flow -   Shareholders confirm Dr. Joerg Re



Job Offers

» Job Offer: Novartis

Last job offers



Website Preview

Link

Medicine and Life Sciences

This site uses cookies and analysis tools to improve the usability of the site. More information. |